A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)

NCT00445094 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2017-02-17

No results posted yet for this study

Summary

The primary objective of this study is a comparison between MK0787B and standard therapy.

Conditions

Interventions

DRUG

MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days

DRUG

Comparator: amikacin / Duration of Treatment: 3 Days

DRUG

Comparator: tazocin / Duration of Treatment: 3 Days

DRUG

Comparator: vancomycin / Duration of Treatment: 3 Days

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2007-01-31
Completion
2007-01-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00445094 on ClinicalTrials.gov